<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article>
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">The Journal Title</journal-id>
      <issn pub-type="epub">0000-000X</issn>
      <publisher>
        <publisher-name>The Publisher Name</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="doi">10.1000/123456</article-id>
      <article-categories>
        <subj-group>
          <subject>Sample Articles</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>A Sample Article Title</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Eve</surname>
            <given-names>Martin Paul</given-names>
          </name>
          <xref ref-type="aff" rid="lincoln"/>
        </contrib>
        <aff id="lincoln">
          <institution>University of Lincoln</institution>
        </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <year>2013</year>
      </pub-date>
      <volume>1</volume>
      <issue>1</issue>
      <fpage>1</fpage>
      <lpage>2</lpage>
      <permissions>
        <copyright-statement>Copyright &#169; 2014, Martin Paul Eve</copyright-statement>
        <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0/">
          <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The citation of this article must include: the name(s) of the authors, the name of the journal, the full URL of the article (in a hyperlinked format if distributed online) and the DOI number of the article.</license-p>
        </license>
      </permissions>
      <self-uri>https://www.martineve.com/</self-uri>
      <abstract>
        <p>This is a sample abstract that forms part of the metadataSample.xml file in meTypeset.</p>
      </abstract>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>Title: Toward a definition of pharmaceutical innovation</title>
      <sec>
        <title>Authors: Steven Morgan, Ruth Lopert, Devon Greyson</title>
        <p>Dr. Morgan is Assistant Professor in the University of British Columbia&#8217;s Department of Health Care and Epidemiology and research lead of the program in pharmaceutical policy at the UBC Centre for Health Services and Policy Research. Email: morgan@chspr.ubc.ca</p>
        <p>Dr. Lopert is Harkness Fellow in Health Care Policy and Practice in the Department of Health Policy at George Washington University, Washington DC. Email: ruth.lopert@gmail.com</p>
        <p>Ms. Devon Greyson is Information Specialist at the UBC Centre for Health Services and Policy Research. Email: devon@chspr.ubc.ca</p>
      </sec>
      <sec>
        <title>Corresponding author</title>
        <p>Steven Morgan</p>
        <p>UBC &#8211; Centre for Health Services and Policy Research</p>
        <p>#201 - 2206 East Mall (<xref rid="TO_LINK" ref-type="bibr" id="ID09511918-f23b-43ce-a26d-a440875093d4">LPC</xref>)</p>
        <p>Vancouver, BC, V6T 1Z3 Canada</p>
        <p>Phone: +1 604-822-7012</p>
        <p>Fax: +1 604-822-5690</p>
        <p>Email: morgan@chspr.ubc.ca</p>
      </sec>
      <sec>
        <title>Author Contributions</title>
        <p>Steve Morgan, guarantor, is responsible for project conception, developing the conceptual framework and drafting original article. Ruth Lopert is responsible for revising the conceptual framework and article for intellectual content. Devon Greyson is responsible for performing literature search, proposing a draft conceptual framework and revising the article. All authors give final approval of the version to be published.</p>
      </sec>
      <sec>
        <title>Funding </title>
        <p>There was no direct funding for this study. Steve Morgan is supported by a New Investigator award from the Canadian Institutes of Health Research (<xref rid="TO_LINK" ref-type="bibr" id="IDc676e68f-b57a-4215-9001-6af26a557c4a">CIHR</xref>) and Scholar Award from the Michael Smith Foundation for Health Research (<xref rid="TO_LINK" ref-type="bibr" id="ID8802d2ad-33fc-464f-8414-7c3036b6d893">MSFHR</xref>). Ruth Lopert gratefully acknowledges the support of the Commonwealth Fund. The views presented here are solely those of the authors and not necessarily those of the <xref rid="TO_LINK" ref-type="bibr" id="ID333c97ea-f941-456f-bd48-e98e266bdbe0">CIHR</xref>, the <xref rid="TO_LINK" ref-type="bibr" id="IDa5923973-138b-4a78-a041-7969a39ccfc2">MSFHR</xref>, or of the Commonwealth Fund, its directors, officers, or staff. </p>
      </sec>
    </sec>
    <sec>
      <title>Word count: 1,484</title>
    </sec>
    <sec>
      <title>Figures and Tables: 1 figure </title>
      <sec>
        <title>Competing Interests: None to declare.</title>
        <p>Abstract</p>
        <p>Despite current debate on ways to promote innovation in the pharmaceutical sector, there is little clarity about what constitutes a pharmaceutical innovation, and therefore potential confusion about what should be pursued, protected and encouraged through policy and clinical practice. We provide a brief review of the definition of innovation, drawing on clinical, economic and business literature, and offer a new conceptual framework for classifying pharmaceutical innovations. Innovation is the application of ideas in ways that effectively address previously unmet needs. A distinction can then therefore be drawn between &#8220;pharmaceutical innovations&#8221; and &#8220;commercial innovations.&#8221; Pharmaceutical innovations must effectively address previously unmet health care needs. New medicines that utilize novel mechanisms to replicate outcomes achievable through other means&#8212;while potentially important to market competition&#8212;do not constitute innovations. Commercial innovations need only generate new profit opportunities; these may or may not be the result of desired pharmaceutical innovations. We conclude that policy should aim to align incentives such that commercial innovations from R&amp;D activities are necessarily those that effectively address previously unmet health care needs.</p>
        <p>&#160;Toward a definition of pharmaceutical innovation</p>
        <p>Ongoing debates in pharmaceutical sector about intellectual property, ADDIN EN.CITE &lt;EndNote&gt;&lt;Cite&gt;&lt;Author&gt;Barton&lt;/Author&gt;&lt;Year&gt;2005&lt;/Year&gt;&lt;RecNum&gt;6692&lt;/RecNum&gt;&lt;record&gt;&lt;rec-number&gt;6692&lt;/rec-number&gt;&lt;foreign-keys&gt;&lt;key app="EN" db-id="e5razrre359x0aetvvexesr5tfx2dpf0v522"&gt;6692&lt;/key&gt;&lt;/foreign-keys&gt;&lt;ref-type name="Journal Article"&gt;17&lt;/ref-type&gt;&lt;contributors&gt;&lt;authors&gt;&lt;author&gt;Barton, J. H.&lt;/author&gt;&lt;author&gt;Emanuel, E. J.&lt;/author&gt;&lt;/authors&gt;&lt;tertiary-authors&gt;&lt;author&gt;Anonymous,&lt;/author&gt;&lt;/tertiary-authors&gt;&lt;/contributors&gt;&lt;titles&gt;&lt;title&gt;The patents-based pharmaceutical development process: Rationale, problems, and potential reforms&lt;/title&gt;&lt;secondary-title&gt;Jama-Journal of the American Medical Association&lt;/secondary-title&gt;&lt;/titles&gt;&lt;periodical&gt;&lt;full-title&gt;Jama-Journal of the American Medical Association&lt;/full-title&gt;&lt;/periodical&gt;&lt;pages&gt;2075&lt;/pages&gt;&lt;volume&gt;294&lt;/volume&gt;&lt;number&gt;16&lt;/number&gt;&lt;dates&gt;&lt;year&gt;2005&lt;/year&gt;&lt;pub-dates&gt;&lt;date&gt;OCT 26&lt;/date&gt;&lt;/pub-dates&gt;&lt;/dates&gt;&lt;accession-num&gt;410&lt;/accession-num&gt;&lt;urls&gt;&lt;/urls&gt;&lt;/record&gt;&lt;/Cite&gt;&lt;Cite&gt;&lt;Author&gt;Hollis&lt;/Author&gt;&lt;Year&gt;2005&lt;/Year&gt;&lt;RecNum&gt;7312&lt;/RecNum&gt;&lt;record&gt;&lt;rec-number&gt;7312&lt;/rec-number&gt;&lt;foreign-keys&gt;&lt;key app="EN" db-id="e5razrre359x0aetvvexesr5tfx2dpf0v522"&gt;7312&lt;/key&gt;&lt;/foreign-keys&gt;&lt;ref-type name="Book Section"&gt;5&lt;/ref-type&gt;&lt;contributors&gt;&lt;authors&gt;&lt;author&gt;Hollis, A.&lt;/author&gt;&lt;/authors&gt;&lt;secondary-authors&gt;&lt;author&gt;Beach, Charles&lt;/author&gt;&lt;author&gt;Chaykowski, Richard &lt;/author&gt;&lt;author&gt;Shortt, Sam &lt;/author&gt;&lt;author&gt;St-Hilaire, France&lt;/author&gt;&lt;author&gt;Sweetman, Arthur&lt;/author&gt;&lt;/secondary-authors&gt;&lt;/contributors&gt;&lt;titles&gt;&lt;title&gt;Drugs for Rare Diseases: Paying for Innovation&lt;/title&gt;&lt;secondary-title&gt;Health Services Restructuring in Canada: New Evidence and New Directions&lt;/secondary-title&gt;&lt;/titles&gt;&lt;volume&gt;in print&lt;/volume&gt;&lt;dates&gt;&lt;year&gt;2005&lt;/year&gt;&lt;/dates&gt;&lt;pub-location&gt;Kingston&lt;/pub-location&gt;&lt;publisher&gt;McGill-Queens University Press&lt;/publisher&gt;&lt;accession-num&gt;598&lt;/accession-num&gt;&lt;urls&gt;&lt;related-urls&gt;&lt;url&gt;http://www.irpp.org/events/archive/nov05JDI/hollis.pdf &lt;/url&gt;&lt;/related-urls&gt;&lt;/urls&gt;&lt;/record&gt;&lt;/Cite&gt;&lt;/EndNote&gt;1,2 pricing and reimbursement, ADDIN EN.CITE &lt;EndNote&gt;&lt;Cite&gt;&lt;Author&gt;USA International Trade Administration&lt;/Author&gt;&lt;Year&gt;2004&lt;/Year&gt;&lt;RecNum&gt;7378&lt;/RecNum&gt;&lt;record&gt;&lt;rec-number&gt;7378&lt;/rec-number&gt;&lt;foreign-keys&gt;&lt;key app="EN" db-id="e5razrre359x0aetvvexesr5tfx2dpf0v522"&gt;7378&lt;/key&gt;&lt;/foreign-keys&gt;&lt;ref-type name="Report"&gt;27&lt;/ref-type&gt;&lt;contributors&gt;&lt;authors&gt;&lt;author&gt;USA International Trade Administration,&lt;/author&gt;&lt;/authors&gt;&lt;/contributors&gt;&lt;titles&gt;&lt;title&gt;Pharmaceutical Price Controls in OECD Countries Implications for U.S. Consumers, Pricing, Research and Development, and Innovation&lt;/title&gt;&lt;/titles&gt;&lt;dates&gt;&lt;year&gt;2004&lt;/year&gt;&lt;/dates&gt;&lt;pub-location&gt;Washington&lt;/pub-location&gt;&lt;publisher&gt;U.S. Department of Commerce&lt;/publisher&gt;&lt;urls&gt;&lt;related-urls&gt;&lt;url&gt;http://www.ita.doc.gov/td/chemicals/drugpricingstudy.pdf&lt;/url&gt;&lt;/related-urls&gt;&lt;/urls&gt;&lt;access-date&gt;11 April 2007&lt;/access-date&gt;&lt;/record&gt;&lt;/Cite&gt;&lt;Cite&gt;&lt;Author&gt;UK&lt;/Author&gt;&lt;Year&gt;2007&lt;/Year&gt;&lt;RecNum&gt;7362&lt;/RecNum&gt;&lt;record&gt;&lt;rec-number&gt;7362&lt;/rec-number&gt;&lt;foreign-keys&gt;&lt;key app="EN" db-id="e5razrre359x0aetvvexesr5tfx2dpf0v522"&gt;7362&lt;/key&gt;&lt;/foreign-keys&gt;&lt;ref-type name="Report"&gt;27&lt;/ref-type&gt;&lt;contributors&gt;&lt;authors&gt;&lt;author&gt;UK&lt;/author&gt;&lt;/authors&gt;&lt;/contributors&gt;&lt;titles&gt;&lt;title&gt;Pharmaceutical Price Regulation Scheme &lt;/title&gt;&lt;/titles&gt;&lt;pages&gt;120&lt;/pages&gt;&lt;dates&gt;&lt;year&gt;2007&lt;/year&gt;&lt;pub-dates&gt;&lt;date&gt;February&lt;/date&gt;&lt;/pub-dates&gt;&lt;/dates&gt;&lt;pub-location&gt;London&lt;/pub-location&gt;&lt;publisher&gt;Office of Fair Trading&lt;/publisher&gt;&lt;urls&gt;&lt;related-urls&gt;&lt;url&gt;http://www.oft.gov.uk/shared_oft/reports/comp_policy/oft885.pdf&lt;/url&gt;&lt;/related-urls&gt;&lt;/urls&gt;&lt;access-date&gt;7 March 2007&lt;/access-date&gt;&lt;/record&gt;&lt;/Cite&gt;&lt;/EndNote&gt;3,4 and public research investments ADDIN EN.CITE &lt;EndNote&gt;&lt;Cite&gt;&lt;Author&gt;Cooksey&lt;/Author&gt;&lt;Year&gt;2006&lt;/Year&gt;&lt;RecNum&gt;7377&lt;/RecNum&gt;&lt;record&gt;&lt;rec-number&gt;7377&lt;/rec-number&gt;&lt;foreign-keys&gt;&lt;key app="EN" db-id="e5razrre359x0aetvvexesr5tfx2dpf0v522"&gt;7377&lt;/key&gt;&lt;/foreign-keys&gt;&lt;ref-type name="Report"&gt;27&lt;/ref-type&gt;&lt;contributors&gt;&lt;authors&gt;&lt;author&gt;Cooksey, David&lt;/author&gt;&lt;/authors&gt;&lt;/contributors&gt;&lt;titles&gt;&lt;title&gt;A review of UK health research funding&lt;/title&gt;&lt;/titles&gt;&lt;dates&gt;&lt;year&gt;2006&lt;/year&gt;&lt;/dates&gt;&lt;pub-location&gt;London&lt;/pub-location&gt;&lt;publisher&gt;Her Majesty&#8217;s Stationery Office&lt;/publisher&gt;&lt;urls&gt;&lt;related-urls&gt;&lt;url&gt;http://www.hm-treasury.gov.uk/media/56F/62/pbr06_cooksey_final_report_636.pdf&lt;/url&gt;&lt;/related-urls&gt;&lt;/urls&gt;&lt;access-date&gt;15 June 2007&lt;/access-date&gt;&lt;/record&gt;&lt;/Cite&gt;&lt;/EndNote&gt;5 have a common denominator: the pursuit of innovation. Yet there is little clarity about what constitutes a true pharmaceutical innovation, creating confusion about what should be encouraged through health policy and clinical practice. In an era of increasing drug development costs, ADDIN EN.CITE &lt;EndNote&gt;&lt;Cite&gt;&lt;Author&gt;Drews&lt;/Author&gt;&lt;Year&gt;20<xref rid="TO_LINK" ref-type="bibr" id="ID24a6ebe9-61b0-47a8-8fad-49b39ce51d53">03</xref>&lt;/Year&gt;&lt;RecNum&gt;7364&lt;/RecNum&gt;&lt;record&gt;&lt;rec-number&gt;7364&lt;/rec-number&gt;&lt;foreign-keys&gt;&lt;key app="EN" db-id="e5razrre359x0aetvvexesr5tfx2dpf0v522"&gt;7364&lt;/key&gt;&lt;/foreign-keys&gt;&lt;ref-type name="Journal Article"&gt;17&lt;/ref-type&gt;&lt;contributors&gt;&lt;authors&gt;&lt;author&gt;Drews, J.&lt;/author&gt;&lt;/authors&gt;&lt;/contributors&gt;&lt;titles&gt;&lt;title&gt;Strategic trends in the drug industry&lt;/title&gt;&lt;secondary-title&gt;Drug Discovery Today&lt;/secondary-title&gt;&lt;/titles&gt;&lt;periodical&gt;&lt;full-title&gt;Drug Discovery Today&lt;/full-title&gt;&lt;/periodical&gt;&lt;pages&gt;411-420&lt;/pages&gt;&lt;volume&gt;8&lt;/volume&gt;&lt;dates&gt;&lt;year&gt;20<xref rid="TO_LINK" ref-type="bibr" id="IDbfabea23-38f5-4938-85da-caaf3b46c9f5">03</xref>&lt;/year&gt;&lt;/dates&gt;&lt;urls&gt;&lt;related-urls&gt;&lt;url&gt;http://www.ingentaconnect.com/content/els/13596446/2003/00000008/00000009/art02690&lt;/url&gt;&lt;url&gt;http://dx.doi.org/10.1016/S1359-6446(03)02690-4 &lt;/url&gt;&lt;/related-urls&gt;&lt;/urls&gt;&lt;/record&gt;&lt;/Cite&gt;&lt;/EndNote&gt;6 and continued disparity between burden of illness and drug research and development, ADDIN EN.CITE 7,8 conceptual clarity may help policy makers and practitioners evaluate, adopt and procure products in ways that appropriately recognize and encourage truly valued pharmaceutical innovation.</p>
      </sec>
      <sec>
        <title>Pharmaceutical Innovation</title>
        <p>Describing a product as innovative implies that it has properties worthy of recognition and reward. This may explain why manufacturers regularly apply the term to new pharmaceuticals. ADDIN EN.CITE &lt;EndNote&gt;&lt;Cite&gt;&lt;Author&gt;PHRMA&lt;/Author&gt;&lt;Year&gt;2007&lt;/Year&gt;&lt;RecNum&gt;7355&lt;/RecNum&gt;&lt;record&gt;&lt;rec-number&gt;7355&lt;/rec-number&gt;&lt;foreign-keys&gt;&lt;key app="EN" db-id="e5razrre359x0aetvvexesr5tfx2dpf0v522"&gt;7355&lt;/key&gt;&lt;/foreign-keys&gt;&lt;ref-type name="Web Page"&gt;12&lt;/ref-type&gt;&lt;contributors&gt;&lt;authors&gt;&lt;author&gt;PHRMA&lt;/author&gt;&lt;/authors&gt;&lt;/contributors&gt;&lt;titles&gt;&lt;title&gt;Innovation.org&lt;/title&gt;&lt;/titles&gt;&lt;volume&gt;2007&lt;/volume&gt;&lt;number&gt;10 April&lt;/number&gt;&lt;dates&gt;&lt;year&gt;2007&lt;/year&gt;&lt;/dates&gt;&lt;urls&gt;&lt;related-urls&gt;&lt;url&gt;http://www.innovation.org/&lt;/url&gt;&lt;/related-urls&gt;&lt;/urls&gt;&lt;/record&gt;&lt;/Cite&gt;&lt;/EndNote&gt;9 It is also why a clear definition of pharmaceutical innovation is required: so that policy and practice recognize the societal value of new pharmaceutical technologies.</p>
        <p>Notions of value depend on perspective. Commercial value, for example, is generally assessed from the perspective of firm profitability. Profits, in turn, can provide incentive to produce value for consumers and society. In markets for everyday commodities consumer value is generally related to preferences over the characteristics of goods and services. In a health care context, consumer preferences are central to determining the relative value of different health outcomes. However, it is the <italic>health outcomes</italic> themselves that give pharmaceuticals societal value. As health care inputs, pharmaceutical products <italic>per se</italic> are of no intrinsic value to patients or to society. Pharmaceuticals are licensed for sale based on whether they safely and efficaciously address a health care need, not because patients might have preferences over their shape, colour, taste or brand. To the extent that characteristics like shape, colour, taste or brand improve health outcomes&#8212;perhaps by increased adherence to prescribed treatment&#8212;it remains the health outcomes that generate value for society. Product characteristics are not unlike surrogate endpoints for clinical trials insofar as they are only of value to the extent that they predict clinical or &#8220;hard&#8221; endpoints. ADDIN EN.CITE &lt;EndNote&gt;&lt;Cite&gt;&lt;Author&gt;Fleming&lt;/Author&gt;&lt;Year&gt;1996&lt;/Year&gt;&lt;RecNum&gt;15766&lt;/RecNum&gt;&lt;record&gt;&lt;rec-number&gt;15766&lt;/rec-number&gt;&lt;foreign-keys&gt;&lt;key app="EN" db-id="e5razrre359x0aetvvexesr5tfx2dpf0v522"&gt;15766&lt;/key&gt;&lt;/foreign-keys&gt;&lt;ref-type name="Journal Article"&gt;17&lt;/ref-type&gt;&lt;contributors&gt;&lt;authors&gt;&lt;author&gt;Fleming, Thomas R.&lt;/author&gt;&lt;author&gt;DeMets, David L.&lt;/author&gt;&lt;/authors&gt;&lt;/contributors&gt;&lt;titles&gt;&lt;title&gt;Surrogate End Points in Clinical Trials: Are We Being Misled?&lt;/title&gt;&lt;secondary-title&gt;Ann Intern Med&lt;/secondary-title&gt;&lt;/titles&gt;&lt;periodical&gt;&lt;full-title&gt;Ann Intern Med&lt;/full-title&gt;&lt;/periodical&gt;&lt;pages&gt;605-613&lt;/pages&gt;&lt;volume&gt;125&lt;/volume&gt;&lt;number&gt;7&lt;/number&gt;&lt;dates&gt;&lt;year&gt;1996&lt;/year&gt;&lt;pub-dates&gt;&lt;date&gt;October 1, 1996&lt;/date&gt;&lt;/pub-dates&gt;&lt;/dates&gt;&lt;urls&gt;&lt;related-urls&gt;&lt;url&gt;http://www.annals.org/cgi/content/abstract/125/7/605 &lt;/url&gt;&lt;/related-urls&gt;&lt;/urls&gt;&lt;/record&gt;&lt;/Cite&gt;&lt;Cite&gt;&lt;Author&gt;Bucher&lt;/Author&gt;&lt;Year&gt;1999&lt;/Year&gt;&lt;RecNum&gt;15767&lt;/RecNum&gt;&lt;record&gt;&lt;rec-number&gt;15767&lt;/rec-number&gt;&lt;foreign-keys&gt;&lt;key app="EN" db-id="e5razrre359x0aetvvexesr5tfx2dpf0v522"&gt;15767&lt;/key&gt;&lt;/foreign-keys&gt;&lt;ref-type name="Journal Article"&gt;17&lt;/ref-type&gt;&lt;contributors&gt;&lt;authors&gt;&lt;author&gt;Bucher, Heiner C.&lt;/author&gt;&lt;author&gt;Guyatt, Gordon H.&lt;/author&gt;&lt;author&gt;Cook, Deborah J.&lt;/author&gt;&lt;author&gt;Holbrook, Anne&lt;/author&gt;&lt;author&gt;McAlister, Finlay A.&lt;/author&gt;&lt;author&gt;for the Evidence-Based Medicine Working, Group&lt;/author&gt;&lt;/authors&gt;&lt;/contributors&gt;&lt;titles&gt;&lt;title&gt;Users&amp;apos; Guides to the Medical Literature: XIX. Applying Clinical Trial Results; A. How to Use an Article Measuring the Effect of an Intervention on Surrogate End Points&lt;/title&gt;&lt;secondary-title&gt;JAMA&lt;/secondary-title&gt;&lt;/titles&gt;&lt;periodical&gt;&lt;full-title&gt;JAMA&lt;/full-title&gt;&lt;abbr-1&gt;JAMA&lt;/abbr-1&gt;&lt;abbr-2&gt;JAMA&lt;/abbr-2&gt;&lt;/periodical&gt;&lt;pages&gt;771-778&lt;/pages&gt;&lt;volume&gt;282&lt;/volume&gt;&lt;number&gt;8&lt;/number&gt;&lt;dates&gt;&lt;year&gt;1999&lt;/year&gt;&lt;pub-dates&gt;&lt;date&gt;August 25, 1999&lt;/date&gt;&lt;/pub-dates&gt;&lt;/dates&gt;&lt;urls&gt;&lt;related-urls&gt;&lt;url&gt;http://jama.ama-assn.org &lt;/url&gt;&lt;/related-urls&gt;&lt;/urls&gt;&lt;electronic-resource-num&gt;10.1001/jama.282.8.771&lt;/electronic-resource-num&gt;&lt;/record&gt;&lt;/Cite&gt;&lt;/EndNote&gt;10,11
            </p>
        <p>Placing the societal value of pharmaceuticals exclusively in the context of health production implies that, while concepts of novelty and innovation are often associated, ADDIN EN.CITE &lt;EndNote&gt;&lt;Cite ExcludeAuth="1"&gt;&lt;Year&gt;1989&lt;/Year&gt;&lt;RecNum&gt;6669&lt;/RecNum&gt;&lt;record&gt;&lt;rec-number&gt;6669&lt;/rec-number&gt;&lt;foreign-keys&gt;&lt;key app="EN" db-id="e5razrre359x0aetvvexesr5tfx2dpf0v522"&gt;6669&lt;/key&gt;&lt;/foreign-keys&gt;&lt;ref-type name="Book"&gt;6&lt;/ref-type&gt;&lt;contributors&gt;&lt;secondary-authors&gt;&lt;author&gt;Anonymous,&lt;/author&gt;&lt;/secondary-authors&gt;&lt;/contributors&gt;&lt;titles&gt;&lt;title&gt;Oxford English Dictionary Online&lt;/title&gt;&lt;/titles&gt;&lt;dates&gt;&lt;year&gt;1989&lt;/year&gt;&lt;/dates&gt;&lt;accession-num&gt;501&lt;/accession-num&gt;&lt;urls&gt;&lt;related-urls&gt;&lt;url&gt;http://dictionary.oed.com/cgi/entry/50117397 &lt;/url&gt;&lt;/related-urls&gt;&lt;/urls&gt;&lt;/record&gt;&lt;/Cite&gt;&lt;/EndNote&gt;12 product novelty alone will not constitute pharmaceutical innovation. New chemical structures or mechanisms of action do not necessarily generate new health outcomes. ADDIN EN.CITE 13,14 To be a pharmaceutical innovation requires some level of effectiveness. Yet, effectiveness also falls short of defining pharmaceutical innovation when considered in isolation. A generic drug, for example, may be effective&#8212;and may therefore provide some value (<xref rid="TO_LINK" ref-type="bibr" id="ID6a1670c2-3152-4126-8d6f-602d23c2a048">e.g., price savings</xref>) to patients and society&#8212;but it would hardly be considered an innovation. Thus, neither novelty nor effectiveness alone is enough to qualify as pharmaceutical innovation. Even the combination of novelty <italic>and </italic>effectiveness is not enough.</p>
        <p>Pharmaceutical innovation requires novelty <italic>of</italic> effectiveness. Pharmaceutical innovations generate value by making new health outcomes possible. A drug can therefore only be considered a pharmaceutical innovation to the extent that it actually meets otherwise unmet or inadequately met health care needs. The extent to which a drug achieves this depends on its effectiveness relative to technologies prevailing when it is introduced. For example, cimetidine, the prototypical histamine2-receptor antagonist (<xref rid="TO_LINK" ref-type="bibr" id="ID9773b108-0353-4452-8252-5a353b3bea00">H2RA</xref>), was considered a pharmaceutical innovation when introduced in 1977 because it addressed a previously inadequately met need. ADDIN EN.CITE &lt;EndNote&gt;&lt;Cite&gt;&lt;Author&gt;Hoogerwerf&lt;/Author&gt;&lt;Year&gt;2006&lt;/Year&gt;&lt;RecNum&gt;7380&lt;/RecNum&gt;&lt;record&gt;&lt;rec-number&gt;7380&lt;/rec-number&gt;&lt;foreign-keys&gt;&lt;key app="EN" db-id="e5razrre359x0aetvvexesr5tfx2dpf0v522"&gt;7380&lt;/key&gt;&lt;/foreign-keys&gt;&lt;ref-type name="Book Section"&gt;5&lt;/ref-type&gt;&lt;contributors&gt;&lt;authors&gt;&lt;author&gt;Hoogerwerf, Willemijntje A.&lt;/author&gt;&lt;author&gt;Pasricha, Pankaj Jay&lt;/author&gt;&lt;/authors&gt;&lt;secondary-authors&gt;&lt;author&gt;Goodman, Louis Sanford&lt;/author&gt;&lt;author&gt;Gilman, Alfred&lt;/author&gt;&lt;author&gt;Brunton, Laurence L.&lt;/author&gt;&lt;author&gt;Lazo, John S.&lt;/author&gt;&lt;author&gt;Parker, Keith L.&lt;/author&gt;&lt;/secondary-authors&gt;&lt;/contributors&gt;&lt;titles&gt;&lt;title&gt;Chapter 36. Pharmacotherapy of Gastric Acidity, Peptic Ulcers, and Gastroesophageal Reflux Disease&lt;/title&gt;&lt;secondary-title&gt;Goodman &amp;amp; Gilman&amp;apos;s the pharmacological basis of therapeutics&lt;/secondary-title&gt;&lt;/titles&gt;&lt;edition&gt;11th&lt;/edition&gt;&lt;keywords&gt;&lt;keyword&gt;Pharmacology.&lt;/keyword&gt;&lt;keyword&gt;Therapeutics.&lt;/keyword&gt;&lt;keyword&gt;Pharmacology.&lt;/keyword&gt;&lt;keyword&gt;Drug Therapy.&lt;/keyword&gt;&lt;/keywords&gt;&lt;dates&gt;&lt;year&gt;2006&lt;/year&gt;&lt;/dates&gt;&lt;pub-location&gt;New York&lt;/pub-location&gt;&lt;publisher&gt;McGraw-Hill&lt;/publisher&gt;&lt;isbn&gt;0071422803&lt;/isbn&gt;&lt;urls&gt;&lt;/urls&gt;&lt;/record&gt;&lt;/Cite&gt;&lt;/EndNote&gt;15 The notion of innovation is time-limited because of competition and technological change. Neither cimetidine nor other H2RAs would be considered innovations today because the outcomes they generate have been established, replicated, and even surpassed.</p>
        <p>Replicating outcomes obtainable with existing treatments is important for economic competition and efficiency but is not innovation. However, surpassing previous levels of performance, or matching previous levels of output more efficiently, would be considered innovation. Again, consider advances in gastroenterology: the first proton pump inhibitor (<xref rid="TO_LINK" ref-type="bibr" id="IDee0d3917-9f3c-4b9e-b9ab-9b12f06f4a44">PPI</xref>), omeprazole, introduced in 1989, was an innovation because, relative to H2RAs, it met a given need with greater efficacy. <xref rid="TO_LINK" ref-type="bibr" id="ID11b7d292-11dc-4aeb-8332-223baa9835bb">PPI</xref>s have since become the mainstay of treatment for acid-related gastrointestinal disease in adults and, without detracting from the value of the outcomes they generate, would no longer be considered innovations.</p>
        <p>A pharmaceutical innovation may be thought of as incremental, substantial, or radical according to the significance of the unmet health care need it addresses (<italic><xref rid="TO_LINK" ref-type="bibr" id="IDc668867d-c5e5-468b-98c8-ec36dd6c57e9">gravity of unmet need</xref></italic>) and the extent to which it improves health outcomes related to that need (<italic><xref rid="TO_LINK" ref-type="bibr" id="ID64b73f38-3a44-4614-abff-2e4234a2a812">comparative effectiveness</xref></italic>)&#8212;see Figure 1. Gravity of the unmet need can be thought of as the gap between an ideal health status and the health status attainable for patients with a given condition using prevailing technologies. The lowest <xref rid="TO_LINK" ref-type="bibr" id="ID11083881-38aa-44c8-81af-c2d63ef07983">gravity of unmet need</xref> (<xref rid="TO_LINK" ref-type="bibr" id="ID785c1b88-1cdf-4944-986e-74355b988569">zero</xref>) would represent conditions for which existing treatments offer a total cure or <xref rid="TO_LINK" ref-type="bibr" id="ID517d5795-0438-4575-abc2-5942d963d65a">one</xref>s for which the underlying need is relatively trivial in terms of health status (<xref rid="TO_LINK" ref-type="bibr" id="ID4a22aafe-393d-4d3f-9866-439372668ffa">e.g., male pattern baldness</xref>). The highest gravity of unmet need (<xref rid="TO_LINK" ref-type="bibr" id="ID9477d63e-a6cf-4330-b91d-9d043aeadda3">one</xref>) would represent conditions for which existing treatments result in a prognosis of death or, perhaps, fates worse than death.</p>
        <fig position="float" orientation="portrait">
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="media/image36.png" id="ID99db51b2-80f2-44a6-abe8-7412fccfd11a" position="float" orientation="portrait" xlink:type="simple">
            <label>Figure 11</label>
            <caption>
              <p>Classifying pharmaceutical innovations</p>
            </caption>
          </graphic>
        </fig>
        <p>Gravity of unmet need establishes the potential for pharmaceutical innovation (i.e., the maximum improvement in health status that a new drug might offer, over and above existing technologies). Actual pharmaceutical innovation depends on the drug&#8217;s comparative effectiveness. Zero comparative effectiveness indicates that the drug offers no change in health status compared to existing treatments for patients affected by the given condition. The highest value of comparative effectiveness (<xref rid="TO_LINK" ref-type="bibr" id="ID7ddde564-75fb-44ad-89d5-d17cdaba84c2">one</xref>) indicates that the drug entirely closes the gap between health status attainable with prevailing treatments and ideal health status. The categories of innovation in Figure 1 are drawn with a lower boarder because a medicine must offer some level of comparative health benefit to be considered an innovation, no matter how grave the condition it aims to remedy.</p>
        <p>The greater the gravity of unmet need being addressed and/or the greater the comparative effectiveness in addressing that need, the greater the degree of pharmaceutical innovation represented by a new treatment. Radical innovations, or &#8220;breakthroughs,&#8221; would be effective treatments for conditions that would otherwise significantly reduce the quality and/or length of life, or treatments that provide major improvements over existing options in cases where the prevailing unmet needs are more moderate. Substantial innovations might offer modest improvements in health outcome for those with moderately grave unmet needs, or substantial improvements over existing treatments in cases where unmet health care needs are less serious. Finally, incremental innovations would be drugs that offer minor to moderate improvements in treatment areas where prevailing unmet needs are moderate to trivial.</p>
        <p>New drugs to treat conditions for which existing therapies offer relatively good outcomes will have little potential for being significant pharmaceutical innovations. Variation within a drug class may generate certain therapeutic advantages but difference <italic>per se</italic> does not constitute innovation. For example, early and late entrants into a drug class might each be more effective or better tolerated among certain population subgroups. However, late entrants will not represent significant pharmaceutical innovation unless they are systematically superior to early ones. The value of products that produce outcomes similar to those achievable with other treatment options lies not in innovation but in the potential competition that they may bring to the marketplace &#8212; such competition would contribute to consumer and social value through reduced costs per outcome achieved.</p>
        <p>Ultimately, it is commercial value that drives investments and activities in private sector. Firms may strive for commercial performance by developing drugs that effectively address grave, unmet health care needs. Firms may also be &#8220;commercially innovative&#8221; without generating pharmaceutical innovations, such as when a marketing campaign builds brand loyalty for a product that does not effectively address unmet health care needs. Indeed, when Figure 1 is viewed from a societal perspective on a global or national basis, it appears that most of the commercial activity in the pharmaceutical market is focussed on product development and marketing in therapeutic areas where new products would, at best, provide incremental advances in population health. This is true not only in terms of the global divide between burden of illness and drug research and development, ADDIN EN.CITE 7,8 but also in terms of the share of product development, marketing, and sales in wealthy countries that is accounted for by medicines offering little or no advances over established treatment alternatives. ADDIN EN.CITE &lt;EndNote&gt;&lt;Cite&gt;&lt;Author&gt;Morgan&lt;/Author&gt;&lt;Year&gt;2005&lt;/Year&gt;&lt;RecNum&gt;3668&lt;/RecNum&gt;&lt;record&gt;&lt;rec-number&gt;3668&lt;/rec-number&gt;&lt;foreign-keys&gt;&lt;key app="EN" db-id="e5razrre359x0aetvvexesr5tfx2dpf0v522"&gt;3668&lt;/key&gt;&lt;/foreign-keys&gt;&lt;ref-type name="Journal Article"&gt;17&lt;/ref-type&gt;&lt;contributors&gt;&lt;authors&gt;&lt;author&gt;Morgan, Steven G.&lt;/author&gt;&lt;author&gt;Bassett, Kenneth L.&lt;/author&gt;&lt;author&gt;Wright, James M.&lt;/author&gt;&lt;author&gt;Evans, Robert G.&lt;/author&gt;&lt;author&gt;Barer, Morris L.&lt;/author&gt;&lt;author&gt;Caetano, Patricia A.&lt;/author&gt;&lt;author&gt;Black, Charlyn D.&lt;/author&gt;&lt;/authors&gt;&lt;/contributors&gt;&lt;titles&gt;&lt;title&gt;&amp;quot;Breakthrough&amp;quot; drugs and growth in expenditure on prescription drugs in Canada&lt;/title&gt;&lt;secondary-title&gt;British Medical Journal&lt;/secondary-title&gt;&lt;/titles&gt;&lt;periodical&gt;&lt;full-title&gt;British Medical Journal&lt;/full-title&gt;&lt;abbr-1&gt;Br. Med. J.&lt;/abbr-1&gt;&lt;abbr-2&gt;Br Med J&lt;/abbr-2&gt;&lt;/periodical&gt;&lt;pages&gt;815-816&lt;/pages&gt;&lt;volume&gt;331&lt;/volume&gt;&lt;number&gt;7520&lt;/number&gt;&lt;dates&gt;&lt;year&gt;2005&lt;/year&gt;&lt;pub-dates&gt;&lt;date&gt;October 8, 2005&lt;/date&gt;&lt;/pub-dates&gt;&lt;/dates&gt;&lt;urls&gt;&lt;related-urls&gt;&lt;url&gt;http://bmj.bmjjournals.com &lt;/url&gt;&lt;/related-urls&gt;&lt;/urls&gt;&lt;/record&gt;&lt;/Cite&gt;&lt;/EndNote&gt;16 
            </p>
        <p>Ultimately, industry is not to blame. The pharmaceutical industry&#8217;s focus on activities of incremental value results from way drugs are appraised, selected, and rewarded by policy makers, practitioners and, to an increasing extent, patients. If a premium was selectively placed on true pharmaceutical innovations&#8212;effective treatments for previously unmet needs&#8212;and competition was encouraged among technologies that replicate otherwise achievable outcomes, then private investments in research and development would be stimulated in areas of greatest value to society. ADDIN EN.CITE &lt;EndNote&gt;&lt;Cite&gt;&lt;Author&gt;UK&lt;/Author&gt;&lt;Year&gt;2007&lt;/Year&gt;&lt;RecNum&gt;7362&lt;/RecNum&gt;&lt;record&gt;&lt;rec-number&gt;7362&lt;/rec-number&gt;&lt;foreign-keys&gt;&lt;key app="EN" db-id="e5razrre359x0aetvvexesr5tfx2dpf0v522"&gt;7362&lt;/key&gt;&lt;/foreign-keys&gt;&lt;ref-type name="Report"&gt;27&lt;/ref-type&gt;&lt;contributors&gt;&lt;authors&gt;&lt;author&gt;UK&lt;/author&gt;&lt;/authors&gt;&lt;/contributors&gt;&lt;titles&gt;&lt;title&gt;Pharmaceutical Price Regulation Scheme &lt;/title&gt;&lt;/titles&gt;&lt;pages&gt;120&lt;/pages&gt;&lt;dates&gt;&lt;year&gt;2007&lt;/year&gt;&lt;pub-dates&gt;&lt;date&gt;February&lt;/date&gt;&lt;/pub-dates&gt;&lt;/dates&gt;&lt;pub-location&gt;London&lt;/pub-location&gt;&lt;publisher&gt;Office of Fair Trading&lt;/publisher&gt;&lt;urls&gt;&lt;related-urls&gt;&lt;url&gt;http://www.oft.gov.uk/shared_oft/reports/comp_policy/oft885.pdf&lt;/url&gt;&lt;/related-urls&gt;&lt;/urls&gt;&lt;access-date&gt;7 March 2007&lt;/access-date&gt;&lt;/record&gt;&lt;/Cite&gt;&lt;/EndNote&gt;4 Thus, when assessing a pharmaceutical to determine whether, and to what extent, it is an &#8220;innovation&#8221; for the purposes of listing, prescribing or pricing decisions, the questions to ask are: does it address previously unmet or inadequately met needs; and, to what extent does it improve outcomes along those dimensions of need?</p>
      </sec>
      <sec>
        <title>References</title>
        <disp-quote>
          <p>2.	Hollis A. Drugs for Rare Diseases: Paying for Innovation. In: C Beach; R Chaykowski; S Shortt et al., editors, translator and editor Health Services Restructuring in Canada: New Evidence and New Directions. Vol. in print. Kingston: McGill-Queens University Press; 2005.</p>
        </disp-quote>
        <disp-quote>
          <p>3.	USA International Trade Administration. Pharmaceutical Price Controls in OECD Countries Implications for U.S. Consumers, Pricing, Research and Development, and Innovation. Washington: U.S. Department of Commerce.</p>
        </disp-quote>
        <disp-quote>
          <p>4.	UK. Pharmaceutical Price Regulation Scheme London: Office of Fair Trading, February.</p>
        </disp-quote>
        <disp-quote>
          <p>5.	Cooksey D. A review of UK health research funding. London: Her Majesty&#8217;s Stationery Office.</p>
        </disp-quote>
        <disp-quote>
          <p>6.	Drews J. Strategic trends in the drug industry. Drug Discovery Today 2003; 8:411-20.</p>
        </disp-quote>
        <disp-quote>
          <p>7.	Trouiller P, Olliaro P, Torreele E et al. Drug development for neglected diseases: a deficient market and a public-health policy failure. Lancet 2002; 359 (<xref rid="TO_LINK" ref-type="bibr" id="ID6b570bf3-22e2-413e-be26-023f32e1fc39">9324</xref>):2188-94.</p>
        </disp-quote>
        <disp-quote>
          <p>8.	Winters DJ. Expanding global research and development for neglected diseases. Bull World Health Organ 2006; 84 (<xref rid="TO_LINK" ref-type="bibr" id="ID675148bb-1e0f-4831-8781-f092f4a2324c">5</xref>):414-6.</p>
        </disp-quote>
        <disp-quote>
          <p>9.	PHRMA. Innovation.org 2007 [cited 2007 10 April].</p>
        </disp-quote>
        <disp-quote>
          <p>10.	Fleming TR, DeMets DL. Surrogate End Points in Clinical Trials: Are We Being Misled? Ann Intern Med 1996; 125 (<xref rid="TO_LINK" ref-type="bibr" id="IDbd2ac7f6-c2dd-422c-b89d-996e6dad5bed">7</xref>):605-13.</p>
        </disp-quote>
        <disp-quote>
          <p>11.	Bucher HC, Guyatt GH, Cook DJ et al. Users' Guides to the Medical Literature: XIX. Applying Clinical Trial Results; A. How to Use an Article Measuring the Effect of an Intervention on Surrogate End Points. JAMA 1999; 2<xref rid="TO_LINK" ref-type="bibr" id="ID58618a26-d8b1-463f-9da9-5c3b3adfe962">8</xref>2 (<xref rid="TO_LINK" ref-type="bibr" id="ID2b2392e3-bba2-4203-b452-51698fb4dc06">8</xref>):771-8.</p>
        </disp-quote>
        <disp-quote>
          <p>12.	Oxford English Dictionary Online. Anonymous, editor; 1989. (<xref rid="TO_LINK" ref-type="bibr" id="ID91e59982-a3a4-48f6-a36c-21032d1a3cd5">Anonymous editor</xref>).</p>
        </disp-quote>
        <disp-quote>
          <p><xref rid="TO_LINK" ref-type="bibr" id="IDa8bcbfd2-0059-483a-97b0-14cc8dd5c8f6">1</xref>3.	Wardell WM, DiRaddo J. The measurement of pharmaceutical innovation. J Clin Pharmacol <xref rid="TO_LINK" ref-type="bibr" id="IDb339daee-d2db-4afb-87ff-897638235b30">1</xref>980; 20 (1):1-9.</p>
        </disp-quote>
        <disp-quote>
          <p>14.	Wardell WM, DiRaddo J, Weintraub M. The measurement of therapeutic value. Journal of Clinical Pharmacology 1980; 20 (<xref rid="TO_LINK" ref-type="bibr" id="ID810ae581-f229-43d2-b786-a92140168f4f">2-3</xref>):77.</p>
        </disp-quote>
        <disp-quote>
          <p>15.	Hoogerwerf WA, Pasricha PJ. Chapter 36. Pharmacotherapy of Gastric Acidity, Peptic Ulcers, and Gastroesophageal Reflux Disease. In: LS Goodman; A Gilman; LL Brunton et al., editors, translator and editor Goodman &amp; Gilman's the pharmacological basis of therapeutics. 11th edn. New York: McGraw-Hill; 2006.</p>
        </disp-quote>
        <disp-quote>
          <p>16.	Morgan SG, Bassett KL, Wright JM et al. "Breakthrough" drugs and growth in expenditure on prescription drugs in Canada. British Medical Journal 2005; 331 (<xref rid="TO_LINK" ref-type="bibr" id="IDb779c8ad-547f-4e65-9d05-6786a2903204">7520</xref>):815-6.</p>
        </disp-quote>
      </sec>
    </sec>
  </body>
  <back/>
</article>
